[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620477":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":61,"id":64,"slug":46,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":46,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":46,"enrollmentInfo":72,"targetDuration":46,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":44,"whyStopped":46,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Kaohsiung Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"bismuth-amoxicillin-vonoprazan triple therapy","ACTIVE_COMPARATOR","vonoprazan 20mg twice a day +tripotassium dicitrate bismuthate 300mg four times a day +amoxicilline 750mg four times a day",[13],"Drug: rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole",{"label":15,"type":10,"description":16,"interventionNames":17},"bismuth-based quadruple therapy","rabeprazole 20mg twice a day+ tripotassium dicitrate bismuthate 300mg four times a day+ tetracycline 500mg four times a day+ metronidazole 250mg four times a day",[18],"Drug: vonoprazan, tripotassium dicitrate bismuthate, amoxicilline",[20,26],{"type":21,"name":22,"description":9,"armGroupLabels":23,"otherNames":24},"DRUG","vonoprazan, tripotassium dicitrate bismuthate, amoxicilline",[15],[25],"triple therapy",{"type":21,"name":27,"description":15,"armGroupLabels":28,"otherNames":29},"rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole",[9],[30],"quadruple therapy",[32],{"name":33,"affiliation":5,"role":34},"Deng-Chyang Wu, MD, PHD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","88673121101","7451","dechwu@yahoo.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Kaohsiung Medical University Hospital","RECRUITING","Kaohsiung City",null,"807","Taiwan",{"type":50,"coordinates":51},"Point",[52,53],120.31333,22.61626,{"lat":53,"lon":52},[56],{"name":57,"role":37,"phone":38,"phoneExt":39,"email":40},"DENG-CHYANG WU, MD, PHD",{"type":34,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"DENG-CHYANG WU","Professor and Physician",[62],{"name":63,"class":6},"Kaohsiung Veterans General Hospital.","100620477",false,"NCT07358130","Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy in the First-line Anti-Helicobacter Pylori Treatment","Inclusion Criteria:\n\n* Subjects with Helicobacter pylori infection\n\nExclusion Criteria:\n\n1. Subjects with known hypersensitivity to the study drug.\n2. Subjects with a history of gastric surgery.\n3. Subjects with severe liver cirrhosis or uremia.\n4. Subjects with a history of malignancy within the past five years.\n5. Pregnant or breastfeeding women.\n6. Subjects currently receiving treatment with atazanavir sulfate or rilpivirine hydrochloride.","ALL","18 Years",{"count":73,"type":74},552,"ESTIMATED","INTERVENTIONAL",[77],"NA","(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.",[80],"Helicobacter Pylori Infection",[82],"Helicobacter pylori eradication","2026-01-13",{"date":85,"type":86},"2026-01-22","ACTUAL",{"date":88,"type":86},"2025-10-21",{"date":90,"type":74},"2027-12-31",{"name":5,"class":6},1]